MULTI SCIENCES
Human DOPA DecarBoxylase/DDC Antibody ELISA Kit
Human DOPA DecarBoxylase/DDC Antibody ELISA Kit
SKU:EK1238
Product Details
| Brand | MultiSciences |
|---|---|
| CatNum | 70-EK1238 |
| Product Name | Human DOPA Decarboxylase/DDC ELISA Kit |
| Customs Name | Human DOPA Decarboxylase/DDC ELISA Kit |
| Application | ELISA |
| Reactivity | Human |
| Assay Type | Sandwich ELISA |
| Suitable Sample Type | serum, plasma, cell culture supernates |
| Format | 96-well strip plate |
| Storage | 4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened) |
| Shipping Condition | 4℃ |
| Sample Volume | 50 μl |
| Sensitivity | 1.02 pg/ml |
| Standard Curve Range | 468.75 - 30000 pg/ml |
| Spike Recovery Range | 81 % - 103 % |
| Mean Spike Recovery | 0.92 |
| CV of Intra plate | 2.0 % - 3.0 % |
| CV of Inter plate | 2.3 % - 3.3 % |
| Components | 96-well polystyrene microplate coated with a monoclonal antibody against DDC Human DDC Standard, lyophilized DDC Detect Antibody Standard Diluent Assay Buffer (10×) Substrate (TMB) Stop Solution Washing Buffer (20×) Plate Covers |
| Describtion | This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human DDC. The Human DOPA Decarboxylase/DDC ELISA is for research use only. Not for diagnostic or therapeutic procedures. DOPA decarboxylase (DDC), also known as aromatic-L-amino acid decarboxylase, is a 54 kDa lyase enzyme. It is a vitamin B6-dependent homodimeric enzyme that catalyzes the decarboxylation of both L-3, 4 -dihydroxyphenylalanine (L-DOPA) and L-5-hydroxytryptophan (5-HTP) to dopamine and serotonin, respectively. In normal dopamine and serotonin neurotransmitter synthesis, DDC is not the rate-limiting step in either reaction. However, DDC becomes the rate-limiting step of dopamine synthesis in patients treated with L-DOPA (such as in Parkinson's Disease), and the rate-limiting step of serotonin synthesis in people treated with 5-HTP (such as in mild depression or dysthymia). DDC is inhibited by Carbidopa outside of the blood brain barrier to inhibit the premature conversion of L-DOPA to dopamine in the treatment of Parkinson's. In humans, DDC is also the rate-limiting enzyme in the formation of trace amine neurotransmitters. Deficiency of DDC is associated with various symptoms as severe developmental delay, oculogyric crises and autonomic dysfunction. |
